Immunitybio Inc（IBRX）财务数据IBRXImmunitybio Inc

Evaluating the bottom line, Immunitybio Inc maintains a gross margin of 99.42%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -120.41%, while the net margin is -449.63%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively IBRX converts its operational activities into shareholder value.

In the context of the broader market, IBRX competes directly with industry leaders such as TGTX and CRNX. With a market capitalization of $8.02B, it holds a significant position in the sector. When comparing efficiency, IBRX's gross margin of 99.42% stands against TGTX's 82.86% and CRNX's 99.39%. Such benchmarking helps identify whether Immunitybio Inc is trading at a premium or discount relative to its financial performance.

ImmunityBio has shown impressive revenue growth, with total revenue increasing from 6,106,000 USD in Q3 2024 to 51,240,000 USD in Q2 2026, indicating a strong upward trend in sales. However, the company continues to report significant net losses, with a net income of -632,782,000 USD in Q1 2026.